Related Experiment Video
Updated: Aug 5, 2025
Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial
Published on: September 29, 2015
Leukocyte- and platelet-rich fibrin in cranial surgery: study protocol for a prospective, parallel-group,
Birgit Coucke1,2, Anaïs Van Hoylandt3, Johannes van Loon4,3
1Research Group Experimental Neurosurgery and Neuroanatomy and the Leuven Brain Institute, Department of Neurosciences, KU Leuven, Leuven, Belgium. birgit.coucke@kuleuven.be.
Background:
CSF leakage is a major complication after cranial surgery, thus, adequate dural closure must be performed. Commercially available fibrin sealants are currently considered the gold standard for dural closure, but problems have been reported regarding safety, efficacy, and costs. This trial aims to investigate autologous leukocyte- and platelet-rich fibrin (L-PRF) as an alternative to commercially available fibrin sealants.
Methods/Design:
This single-blinded, prospective randomized controlled interventional trial aims to demonstrate the non-inferiority of L-PRF compared to commercially available fibrin sealants for dural closure. This trial will include patients undergoing cranial neurosurgery (supratentorial and infratentorial) with intentional opening of the dura. Patients are randomized in a 1:1 fashion comparing L-PRF to commercially available fibrin sealants. The primary endpoint is postoperative CSF leakage within 12 weeks after surgery. Secondary endpoints are complications such as bleeding or wound infections. Additionally, a cost-effectiveness analysis is performed.
Discussion:
With this trial, we will evaluate the safety and efficiency of L-PRF compared to commercially available fibrin sealants.
Trial Registration:
ClinicalTrials.gov NCT03812120. Registered on 22 January 2019.
